El interés en corto de Junee da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Junee. Los datos de interés en corto se actualizan cada dos semanas.

Junee (NASDAQ:JUNE) Bolsa, Informe de interés en corto

Cambria ETF Trust ETF

Junee

Junee Ltd is a holding company that operates through its subsidiary. It is engaged in providing design, fit-out, repair, and maintenance services for commercial and residential buildings. The design services include both the consultation with its staff and the actual design work. Fit-out works include installing protective materials to cover floors or walls, installing or constructing partition walls, installing switches, power outlets, telephone wiring, computer outlet covers, and other electrical and wiring works. Repair and maintenance works include, among other things, replacement of fixtures and fittings, repair and maintenance of cupboards and shelves, and repainting walls and ceilings. Geographically, the company derives all of its revenue from its customers in Hong Kong.

Junee Ltd

<p>Acurx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-13. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Acurx Pharmaceuticals to report an <strong>earnings per share</strong> (EPS) of $-0.14.</p>
<p>The announcement from Acurx Pharmaceuticals is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings Track Record</h3>
<p>During the last quarter, the company reported an EPS beat by $0.01, leading to a 3.13% increase in the share price on the subsequent day.</p>
<p>Here's a look at Acurx Pharmaceuticals's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.18</td>
<td>-0.20</td>
<td>-0.22</td>
<td>-0.24</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.17</td>
<td>-0.17</td>
<td>-0.26</td>
<td>-0.28</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>3.0%</td>
<td>-2.0%</td>
<td>-1.0%</td>
<td>8.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747069525_0.png" alt="eps graph" /></p>
<h3>Acurx Pharmaceuticals Share Price Analysis</h3>
<p>Shares of Acurx Pharmaceuticals were trading at $0.36 as of May 09. Over the last 52-week period, shares are down 81.2%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/ACXP/earnings"><strong>To track all earnings releases for Acurx Pharmaceuticals visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

ACXP

A Look Ahead: Acurx Pharmaceuticals's Earnings Forecast

<p>Goldman Sachs  analyst Noah Poponak   maintains Embraer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERJ#NYSE">ERJ</a>) with a Buy and raises the price target from $54 to $60.</p>


News

Price Target

Analyst Ratings

Embraer-Empresa Brasileira De Aeronautica

Goldman Sachs Maintains Buy on Embraer, Raises Price Target to $60

<p>Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-13. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Tenon Medical will report an <strong>earnings per share</strong> (EPS) of $-1.06.</p>
<p>Tenon Medical bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Past Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS beat by $2.79, leading to a 9.91% drop in the share price on the subsequent day.</p>

<p><img src="https://www.benzinga.com/files/images/story/2025/1747069509_0.png" alt="eps graph" /></p>
<h3>Performance of Tenon Medical Shares</h3>
<p>Shares of Tenon Medical were trading at $1.13 as of May 09. Over the last 52-week period, shares are down 83.67%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<h3>Analyst Opinions on Tenon Medical</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Tenon Medical.</p>
<p>The consensus rating for Tenon Medical is Buy, derived from 1 analyst ratings. An average one-year price target of $3.0 implies a potential 165.49% upside.</p>
<h3>Peer Ratings Overview</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of SINTX Technologies, Strata Skin Sciences and Ekso Bionics Holdings, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for SINTX Technologies, with an average 1-year price target of $30.0, suggesting a potential 2554.87% upside.</li>
<li>Analysts currently favor an Buy trajectory for Strata Skin Sciences, with an average 1-year price target of $6.0, suggesting a potential 430.97% upside.</li>
<li>Analysts currently favor an Buy trajectory for Ekso Bionics Holdings, with an average 1-year price target of $4.67, suggesting a potential 313.27% upside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for SINTX Technologies, Strata Skin Sciences and Ekso Bionics Holdings, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tenon Medical</td>
<td>Buy</td>
<td>-4.70%</td>
<td>$353K</td>
<td>-92.73%</td>
</tr>
<tr>
<td>SINTX Technologies</td>
<td>Buy</td>
<td>-67.07%</td>
<td>$38K</td>
<td>-35.78%</td>
</tr>
<tr>
<td>Strata Skin Sciences</td>
<td>Buy</td>
<td>10.21%</td>
<td>$5.76M</td>
<td>-62.83%</td>
</tr>
<tr>
<td>Ekso Bionics Holdings</td>
<td>Buy</td>
<td>5.01%</td>
<td>$2.71M</td>
<td>-24.75%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Tenon Medical ranks at the bottom for Revenue Growth and Gross Profit, indicating negative growth and lower profit margins compared to peers. However, it ranks at the top for Return on Equity, suggesting better performance in generating profits relative to shareholders' equity. Overall, Tenon Medical's financial performance is mixed compared to its peers.</p>
<h3>Discovering Tenon Medical: A Closer Look</h3>
<p>Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.</p>
<h3>Tenon Medical: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Tenon Medical's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately <strong>-4.7%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Tenon Medical's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-400.91%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Tenon Medical's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-92.73%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Tenon Medical's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-26.98%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.19</strong>.</p>
<p><a href="https://www.benzinga.com/quote/TNON/earnings"><strong>To track all earnings releases for Tenon Medical visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


TNON

A Look Ahead: Tenon Medical's Earnings Forecast

<p>Wells Fargo  analyst Finian O'Shea   maintains Barings BDC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBDC#NYSE">BBDC</a>) with a Equal-Weight and lowers the price target from $9 to $8.5.</p>


BBDC

Wells Fargo Maintains Equal-Weight on Barings BDC, Lowers Price Target to $8.5

<p>Goldman Sachs  analyst Kash Rangan   maintains Definitive Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DH#NASDAQ">DH</a>) with a Neutral and raises the price target from $3 to $3.4.</p>


Goldman Sachs Maintains Neutral on Definitive Healthcare, Raises Price Target to $3.4

<p>Goldman Sachs  analyst Matthew Sykes   maintains Cytek Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTKB#NASDAQ">CTKB</a>) with a Sell and lowers the price target from $3.5 to $3.</p>


CTKB

Goldman Sachs Maintains Sell on Cytek Biosciences, Lowers Price Target to $3

WIIM

Dr. Reddy's Laboratories shares are trading hgher on possible continued strength after reporting better-than-expected Q4 financial results on Friday.

CPSS

CORRECTION: Consumer Portfolio Services Announces The Closing Of A $419.95M Senior Subordinate Asset-Backed Securitization

ADNT

APTV

FOXF

HLLY

LAZR

LCID

MBLY

PATK

RIVN

TSLA

Shares of auto and auto parts stocks are trading higher after the US and China agreed to a temporary reduction in most tariffs on each other's goods. This could alleviate supply chain uncertainty in the sector.

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>HubSpot</strong>.</p>
<p>Looking at options history for HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) we detected 11 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 72% of the investors opened trades with bullish expectations and 0% with bearish.</p>
<p>From the overall spotted trades, 3 are puts, for a total amount of $1,002,330 and 8, calls, for a total amount of $355,075.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $480.0 to $640.0 for HubSpot during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In terms of liquidity and interest, the mean open interest for HubSpot options trades today is 52.75 with a total volume of 278.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for HubSpot's big money trades within a strike price range of $480.0 to $640.0 over the last 30 days.</p>
<h3>HubSpot Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747069356_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>HUBS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$28.0</td>
<td>$21.9</td>
<td>$21.9</td>
<td>$480.00</td>
<td>$334.1K</td>
<td align="right">2</td>
<td align="right">150</td>
</tr>
<tr>
<td>HUBS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$28.0</td>
<td>$21.9</td>
<td>$21.9</td>
<td>$480.00</td>
<td>$334.1K</td>
<td align="right">2</td>
<td align="right">150</td>
</tr>
<tr>
<td>HUBS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$28.0</td>
<td>$21.9</td>
<td>$21.9</td>
<td>$480.00</td>
<td>$334.1K</td>
<td align="right">2</td>
<td align="right">150</td>
</tr>
<tr>
<td>HUBS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$21.6</td>
<td>$19.5</td>
<td>$21.6</td>
<td>$610.00</td>
<td>$64.8K</td>
<td align="right">85</td>
<td align="right">44</td>
</tr>
<tr>
<td>HUBS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$21.6</td>
<td>$19.5</td>
<td>$21.6</td>
<td>$610.00</td>
<td>$64.8K</td>
<td align="right">85</td>
<td align="right">44</td>
</tr>
</tbody>
</table>
</p>
<h3>About HubSpot</h3>
<p>HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.</p>
<p>In light of the recent options history for HubSpot, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Current Position of HubSpot</h3>
<ul>
<li>With a trading volume of 611,717, the price of HUBS is up by 8.34%, reaching $653.32.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 86 days from now.</li>
</ul>
<h3>Expert Opinions on HubSpot</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $769.4.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Oppenheimer continues to hold a Outperform rating for HubSpot, targeting a price of $750.<br />
&#x2A; An analyst from Morgan Stanley has decided to maintain their Overweight rating on HubSpot, which currently sits at a price target of $752.<br />
&#x2A; Reflecting concerns, an analyst from Raymond James lowers its rating to Outperform with a new price target of $825.<br />
&#x2A; Consistent in their evaluation, an analyst from Jefferies keeps a Buy rating on HubSpot with a target price of $700.<br />
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Buy rating on HubSpot with a target price of $820. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest HubSpot options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Options

Markets

HUBS

HubSpot's Options Frenzy: What You Need to Know

<p>Goldman Sachs  analyst James Yaro   maintains Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) with a Neutral and raises the price target from $189 to $209.</p>


COIN

Goldman Sachs Maintains Neutral on Coinbase Global, Raises Price Target to $209

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>AbbVie</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with ABBV, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 8 options trades for AbbVie.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 62% bullish and 37%, bearish.</p>
<p>Out of all of the options we uncovered, 7 are puts, for a total amount of $806,471, and there was 1 call, for a total amount of $65,475.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $150.0 to $185.0 for AbbVie over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in AbbVie's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to AbbVie's substantial trades, within a strike price spectrum from $150.0 to $185.0 over the preceding 30 days.</p>
<h3>AbbVie 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747069351_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$0.9</td>
<td>$0.71</td>
<td>$0.88</td>
<td>$180.00</td>
<td>$440.0K</td>
<td>12.2K</td>
<td>10.2K</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$0.39</td>
<td>$0.08</td>
<td>$0.18</td>
<td>$170.00</td>
<td>$108.0K</td>
<td>11.1K</td>
<td>10.3K</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$0.86</td>
<td>$0.71</td>
<td>$0.88</td>
<td>$180.00</td>
<td>$88.0K</td>
<td>12.2K</td>
<td>10.2K</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$43.65</td>
<td>$42.4</td>
<td>$43.65</td>
<td>$150.00</td>
<td>$65.4K</td>
<td>125</td>
<td>0</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$8.7</td>
<td>$8.6</td>
<td>$8.6</td>
<td>$185.00</td>
<td>$56.7K</td>
<td>737</td>
<td>137</td>
</tr>
</tbody>
</table>
</p>
<h3>About AbbVie</h3>
<p>AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).</p>
<p>Having examined the options trading patterns of AbbVie, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Where Is AbbVie Standing Right Now?</h3>
<ul>
<li>With a trading volume of 6,249,708, the price of ABBV is up by 3.85%, reaching $191.72.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 73 days from now.</li>
</ul>
<h3>What The Experts Say On AbbVie</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $219.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Evercore ISI Group continues to hold a Outperform rating for AbbVie, targeting a price of $205.<br />
&#x2A; Reflecting concerns, an analyst from Guggenheim lowers its rating to Buy with a new price target of $214.<br />
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for AbbVie, targeting a price of $250.<br />
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $210.<br />
&#x2A; An analyst from Guggenheim persists with their Buy rating on AbbVie, maintaining a target price of $216. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for AbbVie with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


ABBV

AbbVie Unusual Options Activity

<p>Deep-pocketed investors have adopted a bullish approach towards ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in NOW usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 28 extraordinary options activities for ServiceNow. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 64% leaning bullish and 17% bearish. Among these notable options, 5 are puts, totaling $143,900, and 23 are calls, amounting to $1,279,762.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $800.0 to $1500.0 for ServiceNow during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for ServiceNow's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of ServiceNow's whale trades within a strike price range from $800.0 to $1500.0 in the last 30 days. </p>
<h3>ServiceNow Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747069346_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$289.6</td>
<td>$278.0</td>
<td>$286.0</td>
<td>$890.00</td>
<td>$286.0K</td>
<td align="right">35</td>
<td align="right">10</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$156.5</td>
<td>$149.9</td>
<td>$152.8</td>
<td>$900.00</td>
<td>$152.8K</td>
<td align="right">127</td>
<td align="right">10</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$103.0</td>
<td>$102.0</td>
<td>$102.0</td>
<td>$930.00</td>
<td>$102.0K</td>
<td align="right">47</td>
<td align="right">10</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$140.8</td>
<td>$136.6</td>
<td>$138.7</td>
<td>$920.00</td>
<td>$69.3K</td>
<td align="right">72</td>
<td align="right">5</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/21/25</td>
<td>$25.9</td>
<td>$19.3</td>
<td>$24.0</td>
<td>$1300.00</td>
<td>$60.0K</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</p>
<h3>About ServiceNow</h3>
<p>ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management, expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service.</p>
<p>Following our analysis of the options activities associated with ServiceNow, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of ServiceNow</h3>
<ul>
<li>Trading volume stands at 605,369, with NOW's price up by 3.01%, positioned at $1009.54.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 72 days.</li>
</ul>
<h3>What The Experts Say On ServiceNow</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $1096.8.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; In a cautious move, an analyst from JMP Securities downgraded its rating to Market Outperform, setting a price target of $1300.<br />
&#x2A; An analyst from Scotiabank has decided to maintain their Sector Outperform rating on ServiceNow, which currently sits at a price target of $1075.<br />
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on ServiceNow with a target price of $969.<br />
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on ServiceNow with a target price of $1020.<br />
&#x2A; An analyst from Piper Sandler has decided to maintain their Overweight rating on ServiceNow, which currently sits at a price target of $1120. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for ServiceNow, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


ServiceNow's Options: A Look at What the Big Money is Thinking

CNH Industrial shares are trading higher after UBS raised its price target on the stock from $13 to $16.

<p>Wells Fargo  analyst Finian O'Shea   maintains Prospect Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSEC#NASDAQ">PSEC</a>) with a Underweight and lowers the price target from $3.5 to $3.</p>


PSEC

Wells Fargo Maintains Underweight on Prospect Capital, Lowers Price Target to $3

ACDC

ARIS

CHRD

CIVI

CLNE

CRGY

FANG

GPRE

LBRT

PTEN

PUMP

TRGP

VIST

WFRD

Shares of energy stocks are trading higher amid a rise in the price of oil after the US and China agreed to a temporary reduction in most tariffs. The commodity may be experiencing strength amid escalating conflict between Pakistan and India.

WTRG

Essential Utilities shares are trading lower following Q1 financial results.

<p>Goldman Sachs  analyst Mike Harris   maintains Cleveland-Cliffs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) with a Buy and lowers the price target from $13 to $11.25.</p>


Goldman Sachs Maintains Buy on Cleveland-Cliffs, Lowers Price Target to $11.25

<p>In the current session, the stock is trading at $31.47, after a <strong>1.16%</strong> increase. Over the past month, <strong>Enterprise Prods Partners Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPD#NYSE">EPD</a>)</strong> stock increased by <strong>2.08%</strong>, and in the past year, by <strong>9.06%</strong>. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.</p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1747069257_0.png" alt="Past Year Chart" /></p>

<h3>Enterprise Prods Partners P/E Compared to Competitors</h3>
<p>The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. </p>
<p>Compared to the aggregate P/E ratio of the <strong>19.96</strong> in the Oil, Gas &amp; Consumable Fuels industry, Enterprise Prods Partners Inc. has a lower P/E ratio of <strong>11.65</strong>. Shareholders might be inclined to think that  the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1747069257_1.png" alt="Guage" /></p>

<p>In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes. </p>


Intraday Update

P/E Ratio Insights for Enterprise Prods Partners

<p>Wells Fargo  analyst Richard Garchitorena   maintains CF Industries Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CF#NYSE">CF</a>) with a Overweight and raises the price target from $96 to $98.</p>


Wells Fargo Maintains Overweight on CF Industries Holdings, Raises Price Target to $98

Contracts

Press Releases

Junee Limited's Subsidiary ASPAC AI Computing Enters Strategic Agreement with PanaAI Technology for Advanced AI Infrastructure

Junee Limited Announces Financing Round of Up to US$40 Million to Establish AI (Artificial Intelligence) Supercomputing Center in Australia

Junee Limited Announces the Acquisition of a 51% Stake in MindEnergy, a Provider of AI Server Design and Software Solutions, Aiming to Accelerate the Development of AI Training and Inference Servers and Enhance AI Computing Capabilities Using Advanced Open-Source AI Models Such as DeepSeek R1 and Meta Llama 3

JUNE

Comments

Junee

Interés en corto

Junee (NASDAQ:JUNE) Bolsa, Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL